<DOC>
	<DOCNO>NCT01307267</DOCNO>
	<brief_summary>A study PF-05082566 , 4-1BB agonist monoclonal antibody ( mAb ) , patient solid tumor b-cell lymphoma , combination rituximab patient CD20 positive Non-Hodgkin 's Lymphoma ( NHL ) .</brief_summary>
	<brief_title>A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Inclusion Criteria Portion A : Histological cytological diagnosis advanced/metastatic solid tumor malignancy B cell lymphoma , curative therapy available . Portion A expansion include patient documented disease progression checkpoint inhibitor ( anti CTLA 4 , anti PD1/PD L1 antibody ) per RECIST criterion . Tumor type include metastatic melanoma , renal cell carcinoma ( RCC ) , nonsmall cell lung cancer ( NCSLC ) squamous cell carcinoma head neck ( SCCHN ) . Patients dose expansion stage require provide archival baseline ( obtained screen period ) tumor biopsy . Portion B : Histological confirm relapsed refractory CD20 positive NHL curative therapy available . Patients enrolled expansion cohort must archival tissue available , sample within 6 month study entry . The Expansion cohort include patient FL DLBCL relapse refractory disease . Measurable disease least one extranodal tumor mass &gt; 1.0 cm great transverse diameter ( GTD ) case malignant lymph node &gt; 1.5 cm GTD . ECOG performance status ≤ 1 . Adequate bone marrow function , Portion A : absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L , platelet count ≥100 x 109/L , hemoglobin &gt; 9.0 g/dL . For Portion B : ANC ≥ 1.0 x 109/L , platelet count ≥ 75 x 109/L , hemoglobin ≥ 8.0 g/dL . In case , patient must transfusion independent least 14 day prior screen . Serum creatinine ≤ 2 x ULN estimate creatinine clearance ≥ 50 ml/min . Total serum bilirubin ≤ 1.5 x ULN unless patient document Gilbert syndrome AST ALT ≤ 2.5 x ULN . Exclusion Criteria Patients know symptomatic brain metastasis require steroid . Prior allogeneic hematopoietic stem cell transplant . Immunosuppressive regimen involve systemic corticosteroid within 14 day first dose study treatment . Therapeutic experimental monoclonal antibody within 28 day prior radiation therapy within 14 day first dose study drug . Autoimmune disorder diseases compromise impair immune system . Unstable serious concurrent medical condition previous 6 month . Prior therapy anti CD137 monoclonal antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Advanced malignancy</keyword>
</DOC>